OncoMatch

OncoMatch/Clinical Trials/NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Is NCT07277413 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including IDE892 and IDE397 for nsclc adenocarcinoma.

Phase 1RecruitingIDEAYA BiosciencesNCT07277413Data as of May 2026

Treatment: IDE892 · IDE397 — This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Gastric Cancer

Esophageal Carcinoma

Urothelial Carcinoma

Mesothelioma

Biomarker criteria

Required: MTAP homozygous loss

evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)

Disease stage

Metastatic disease required

locally advanced recurrent or metastatic solid tumor type of interest

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 3 prior lines
Min 1 prior line

Must have received: platinum-based chemotherapy — metastatic

NSCLC that has progressed after prior treatment with platinum chemotherapy

Must have received: anti-PD-1 therapy — metastatic

NSCLC that has progressed after prior treatment with ... a PD-1/PD-L1 inhibitor (unless contraindicated or participant developed intolerance) in the metastatic setting

Cannot have received: MAT2A inhibitor

Previous treatment with a MAT2A inhibitor

Cannot have received: Protein arginine N-methyltransferase (PRMT) inhibitor

Previous treatment with a ... PRMT inhibitor

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate organ function

Liver function

adequate organ function

Have adequate bone marrow and organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Sarah Cannon Research Institute at Florida Cancer Specialists · Orlando, Florida
  • Nebraska Cancer Specialists · Omaha, Nebraska
  • Columbia University Irving Medical Center · New York, New York
  • Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University · Philadelphia, Pennsylvania
  • Sarah Cannon Research Institute · Nashville, Tennessee

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify